Cost-Effectiveness Analysis of Interventions for Tuberculosis Control: DALYs Versus QALYs (original) (raw)
van der Werf MJ, Langendam MW, Sandgren A, Manissero D. Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int J Tuberc Lung Dis. 2012;16:288–96. ArticlePubMed Google Scholar
D’Ambrosio L, Centis R, Migliori GB. Multidrug-resistant tuberculosis. N Engl J Med. 2012;367:2154 (author reply 2155-2156). ArticlePubMed Google Scholar
World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva: World Health Organization; 2013.
European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2013. Stockholm: European Centre for Disease Prevention and Control; 2013.
Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J. 2014;43:554–65. ArticlePubMed Google Scholar
Mwaba P, McNerney R, Grobusch MP, O’Grady J, Bates M, Kapata N, Maeurer M, Zumla A. Achieving STOP TB Partnership goals: perspectives on develop-ment of new diagnostics, drugs and vaccines for tuberculosis. Trop Med Int Health. 2011;16:819–27. ArticlePubMed Google Scholar
Chang K, Lu W, Wang J, Zhang K, Jia S, Li F, Deng S, Chen M. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect. 2012;64:580–8. ArticlePubMed Google Scholar
Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360:2397–405. ArticleCASPubMed Google Scholar
Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366:2151–60. ArticleCASPubMed Google Scholar
NICE. Guide to the methods of technology appraisal. Issued: June 2008.
Miller TL, McNabb SJN, Hilsenrath P, Pasipanodya J, Weis SE. Personal and societal health quality lost to tuberculosis. PLoS ONE. 2009;4:e5080. ArticlePubMedPubMed Central Google Scholar
European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2012. Stockholm: European Centre for Disease Prevention and Control; 2012.
Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–9. ArticleCASPubMed Google Scholar
RKI. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2011. Robert Koch-Institut, Berlin; 2013.
Diel R, Rutz S, Castell S, Schaberg T. Tuberculosis: cost of illness in Germany. Eur Respir J. 2012;40:143–51. ArticlePubMed Google Scholar
Baral SC, Aryal Y, Bhattrai R, King R, Newell JN. The importance of providing counselling and financial support to patients receiving treatment for multi-drug resistant TB: mixed method qualitative and pilot intervention studies. BMC Public Health. 2014;14:46. ArticlePubMedPubMed Central Google Scholar
Tsevat J, Taylor WC, Wong JB, et al. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis. 1988;137:215–22. ArticleCASPubMed Google Scholar
Porco TC, Lewis B, Marseille E, Grinsdale J, Flood JM, Royce SE. Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants. BMC Public Health. 2006;6:157. ArticlePubMedPubMed Central Google Scholar
Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM, Sterling TR, Villarino ME, Mac Kenzie WR. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis. 2013;17:1531–7. ArticleCASPubMed Google Scholar
Holland DP, Gillian D, Sanders GD, Carol D, Hamilton CD, Stout JE. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med. 2009;179:1055–60. ArticlePubMedPubMed Central Google Scholar
Choi HW, Miele K, Dowdy D, Shah M. Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States. Int J Tuberc Lung Dis. 2013;17:1328–35. ArticleCASPubMedPubMed Central Google Scholar
de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med. 2009;169:179–87. ArticlePubMed Google Scholar
Guo N, Marra F, Marra CA. Measuring health-related quality of life in tuberculosis: a systematic review. Health Qual Life Outcomes. 2009;7:14. ArticlePubMedPubMed Central Google Scholar
Bauer M, Leavens A, Schwartzman K. A systematic review and meta-analysis of the impact of tuberculosis on health-related quality of life. Qual Life Res. 2013;22:2213–35. ArticleCASPubMedPubMed Central Google Scholar
Guo N, et al. Health state utilities in latent and active tuberculosis. Value Health. 2008;11:1154–61. ArticlePubMed Google Scholar
Dhingra VK, Rajpal S. Health related quality of life (HRQL) scoring in tuberculosis. Indian J Tuberc. 2003;50:99–104. Google Scholar
Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38:516–28. ArticleCASPubMed Google Scholar
Resch SC, Salomon JA, Murray M, Weinstein MC. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med. 2006;3:e241. ArticlePubMedPubMed Central Google Scholar
Winetsky DE, Negoescu DM, DeMarchis EH, Almukhamedova O, Dooronbekova A, Pulatov D, Vezhnina N, Owens DK, Goldhaber-Fiebert JD. Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and Eastern Europe: a cost-effectiveness analysis. PLoS Med. 2012;9:e1001348. ArticleCASPubMedPubMed Central Google Scholar
The World Bank. World Development Report 1993: investing in health World Bank and Oxford University Press; 1993.
Murray CJL, Lopez AD (eds). Global health statistics: a compendium of incidence, prevalence and mortality estimates for over 200 conditions (Global Burden of Disease and Injury Series). Boston (MA): Harvard School of Public Health, 1996
Prüss-Üstün A, Mathers C, Corvalán C, Woodward A. Introduction and methods: assessing the environmental burden of disease at national and local levels. Geneva: World Health Organization, 2003
Mathers CD, Vos T, Lopez AD, Salomon J, Ezzati M, editors. National burden of disease studies: a practical guide. 2nd ed. Geneva: World Health Organization; 2001. Google Scholar
Grosse SD, Lollar DJ, Campbell VA, Chamie M. Disability and disability-adjusted life years: not the same. Public Health Rep. 2009;124:197–202. PubMedPubMed Central Google Scholar
Murray CJL, Lopez AD (eds). Global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 (Global Burden of Disease and Injury Series). Boston (MA): Harvard University Press, 1996.
Murray CJL. Global burden of disease—quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72:429–45. CASPubMedPubMed Central Google Scholar
Murray CJL, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ. 1994;72:495–509. CASPubMedPubMed Central Google Scholar
Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan. 2001;16:326–31. ArticleCASPubMed Google Scholar
Tan-Torres Edejer T, Baltussen R, Adam T, et al. editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: WHO, 2003.
Global burden of disease 2004 update: disability weights for diseases and conditions. Geneva: World Health Organization, 2004:1–9.
Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–223. ArticlePubMed Google Scholar